Potential molecular approaches for the early diagnosis of lung cancer (Review)

Molecular Medicine Reports

Volumn 6, Issue 5, 2012, Pages 931-936

  Oak, Chul Ho ^a   Wilson, Donald ^b   Lee, Hu Jang ^c   Lim, Ho Ju ^d   Park, Eun Kee ^a  

^a Kosin University   (South Korea)

^b UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^c Gyeongsang National University   (South Korea)

^d National Institute of Environmental Research   (South Korea)

Author keywords

Biomarkers; Early diagnosis; Epigenomics; Lung cancer

Indexed keywords

BRCA1 ASSOCIATED RING DOMAIN PROTEIN 1; CARCINOEMBRYONIC ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYTOKERATIN 19 FRAGMENT; MESSENGER RNA; MICRORNA; NEURON SPECIFIC ENOLASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROGASTRIN RELEASING PEPTIDE; PROTEIN P53; TRANSFORMING GROWTH FACTOR BETA2;

BRONCHOSCOPY; CANCER SCREENING; CPG ISLAND; EPIGENETICS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION; GENE SILENCING; HUMAN; LUNG CANCER; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL RATE;

EARLY DETECTION OF CANCER; HUMANS; LUNG NEOPLASMS; NANOTECHNOLOGY; NEOPLASTIC CELLS, CIRCULATING; PROTEOMICS; RNA, MESSENGER; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84866459936     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2012.1042     Document Type: Review

References (74)

1. Lee YS, Oh YM, Shim TS, Kim WS, An JS, Choi CM and Jang SH: The clinical outcomes of photodynamic therapy in early lung cancer patients. Tuberc Respir Dis 71: 266-270, 2011.
2. Alberg AJ, Ford JG and Samet JM; American College of Chest Physicians: Epidemiology of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 29S-55S, 2007. (Pubitemid 47502798)
3. Ferlay J, Shin HR, Bray F, Forman D, Mathers C and Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917, 2010.
4. Ministry for Health, Welfare and Family Affairs: 2008 Annual Report of Cancer Statistics in Korea. Ministry for Health, Welfare and Family Affairs, Seoul, 2010.
5. Molina R, Filella X, Auge JM, et al: Tumor markers (CEA, CA 125, CYFRA 21-1, SCC, and NSE) in patients with non-small cell lung cancer as an aid in histological diagnosis, and prognosis. Comparison with the main clinical and pathological prognostic factors. Tumour Biol 24: 209-218, 2003. (Pubitemid 37500571)
6. American Cancer Society: Cancer Prevention & Early Detection Facts & Figures, 2011. American Cancer Society, Atlanta, 2011.
7. Scott WJ, Howington J, Feigenberg S, Movsas B and Pisters K; American College of Chest Physicians: Treatment of non-small cell lung cancer stage I and stage II: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 132: 234S-242S, 2007. (Pubitemid 47502810)
8. Hirsch FR, Merrick DT and Franklin WA: Role of biomarkers for early detection of lung cancer and chemoprevention. Eur Respir J 19: 1151-1158, 2002. (Pubitemid 34649633)
9. Brambilla C, Fievet F, Jeanmart M, de Fraipont F, Lantuejoul S, Frappat V, Ferretti G, Brichon PY and Moro-Sibilot D: Early detection of lung cancer: role of biomarkers. Eur Respir J Suppl 39: 36S-44S, 2003. (Pubitemid 36125635)
10. Brower V: Biomarker studies abound for early detection of lung cancer. J Natl Cancer Inst 101: 11-13, 2009.
11. Peng G, Tisch U, Adams O, Hakim M, Shehada N, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A and Haick H: Diagnosing lung cancer in exhaled breath using gold nanoparticles. Nat Nanotechnol 4: 669-673, 2009.
12. van Klaveren RJ, Oudkerk M, Prokop M, et al: Management of lung nodules detected by volume CT scanning. N Engl J Med 361: 2221-2229, 2009.
13. Yau G, Lock M and Rodrigues G: Systematic review of baseline low-dose CT lung cancer screening. Lung Cancer 58: 161-170, 2007. (Pubitemid 47513259)
14. Ilie M, Mazure NM, Hofman V, Ammadi RE, Ortholan C, Bonnetaud C, Havet K, Venissac N, Mograbi B, Mouroux J, Pouysségur J and Hofman P: High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer. Br J Cancer 102: 1627-1635, 2010.
15. Yee J, Sadar MD, Sin DD, Kuzyk M, Xing L, Kondra J, McWilliams A, Man SF and Lam S: Connective tissue-activating peptide III: a novel blood biomarker for early lung cancer detection. J Clin Oncol 27: 2787-2792, 2009.
16. Patz EF, Campa MJ, Gottlin EB, Kusmartseva I, Guan XR and Herndon JE II: Panel of serum biomarkers for the diagnosis of lung cancer. J Clin Oncol 25: 5578-5583, 2007.
17. Palmisano WA, Divine KK, Saccomanno G, Gilliland FD, Baylin SB, Herman JG and Belinsky SA: Predicting lung cancer by detecting aberrant promoter methylation in sputum. Cancer Res 60: 5954-5958, 2000.
18. Belinsky SA, Klinge DM, Dekker JD, Smith MW, Bocklage TJ, Gilliland FD, Crowell RE, Karp DD, Stidley CA and Picchi MA: Gene promoter methylation in plasma and sputum increases with lung cancer risk. Clin Cancer Res 11: 6505-6511, 2005. (Pubitemid 41338988)
19. Gray RD, Duncan A, Noble D, Imrie M, O'Reilly DS, Innes JA, Porteous DJ, Greening AP and Boyd AC: Sputum trace metals are biomarkers of inflammatory and suppurative lung disease. Chest 137: 635-641, 2010.
20. Kennedy TC, Miller Y and Prindiville S: Screening for lung cancer revisited and the role of sputum cytology and fluorescence bronchoscopy in a high-risk group. Chest 117: 72S-79S, 2000. (Pubitemid 30225144)
21. Hirsch J, Hansen KC, Burlingame AL and Matthay MA: Proteomics: current techniques and potential applications to lung disease. Am J Physiol Lung Cell Mol Physiol 287: L1-L23, 2004. (Pubitemid 38787645)
22. Sung HJ and Cho JY: Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 41: 615-625, 2008.
23. Potti A, Mukherjee S, Petersen R, et al: A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 355: 570-580, 2006. (Pubitemid 44200650)
24. Pleasance ED, Stephens PJ, O'Meara S, et al: A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature 463: 184-190, 2010.
25. Mitsudomi T and Yatabe Y: Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci 98: 1817-1824, 2007. (Pubitemid 350002184)
26. McDermott U, Downing JR and Stratton MR: Genomics and the continuum of cancer care. N Engl J Med 364: 340-350, 2011.
27. Verma M and Manne U: Genetic and epigenetic biomarkers in cancer diagnosis and identifying high risk populations. Crit Rev Oncol Hematol 60: 9-18, 2006. (Pubitemid 44349070)
28. Habis AH, Vernon SD, Lee DR, Verma M and Unger U: Molecular quality of exfoliated cervical cells: implications for molecular epidemiology and biomarker discovery. Cancer Epidemiol Biomarkers Prev 13: 492-496, 2004. (Pubitemid 38737478)
29. Martin KJ, Fournier MV, Reddy GP and Pardee AB: A need for basic research on fluid-based early detection biomarkers. Cancer Res 70: 5203-5206, 2010.
30. Baylin SB: DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-S11, 2005.
31. Belinsky SA: Gene-promoter hypermethylation as a biomarker in lung cancer. Nat Rev Cancer 4: 707-717, 2004.
32. Parker CE, Pearson TW, Anderson NL and Borchers CH: Mass-spectrometry- based clinical proteomics-a review and prospective. Analyst 135: 1830-1838, 2010.
33. Qian B, Zhang H, Zhang L, Zhou X, Yu H and Chen K: Association of genetic polymorphisms in DNA repair pathway genes with non-small cell lung cancer risk. Lung Cancer 73: 138-146, 2011.
34. Chatterjee SK and Zetter BR: Cancer biomarkers: knowing the present and predicting the future. Future Oncol 1: 37-50, 2005.
35. Verma M: Human epigenome and cancer. In: Human Genome Epidemiology. Khoury M, Bedrosian SR, Gwinn M, Higgins JPT, Ioannidis JPA and Little J (eds). 2nd edition. Oxford University Press, London, pp551-558, 2009.
36. Sidransky D: Emerging molecular markers of cancer. Nat Rev Cancer 2: 210-219, 2002.
37. Zabarovsky ER, Lerman MI and Minna JD: Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 21: 6915-6935, 2002. (Pubitemid 35221938)
38. Xue X, Zhu YM and Woll PJ: Circulating DNA and lung cancer. Ann NY Acad Sci 1075: 154-164, 2006. (Pubitemid 44532779)
39. Mao L, Lee JS, Kurie JM, et al: Clonal genetic alterations in the lungs of current and former smokers. J Natl Cancer Inst 89: 857-862, 1997. (Pubitemid 27268450)
40. Wistuba II, Behrens C, Milchgrub S, Bryant D, Hung J, Minna JD and Gazdar AF: Sequential molecular abnormalities are involved in the multistage development of squamous cell lung carcinoma. Oncogene 18: 643-650, 1999. (Pubitemid 29080321)
41. Verma M and Srivastava S: Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 3: 755-763, 2002. (Pubitemid 35446745)
42. Verma M and Kumar D: Application of mitochondrial genome information in cancer epidemiology. Clin Chim Acta 383: 41-50, 2007. (Pubitemid 47022991)
43. Enokida H, Shiina H, Igawa M, et al: CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res 64: 5956-5962, 2004. (Pubitemid 39129391)
44. Kaneuchi M, Sasaki M, Tanaka Y, Shiina H, Verma M, Ebina Y, Nomura E, Yamamoto R, Sakuragi N and Dahiya R: Expression and methylation status of 14-3-3 sigma gene can characterize the different histological features of ovarian cancer. Biochem Biophys Res Commun 316: 1156-1162, 2004. (Pubitemid 38369074)
45. Velculescu VE, Zhang L, Vogelstein B and Kinzler KW: Serial analysis of gene expression. Science 270: 484-487, 1995.
46. Showe MK, Vachani A, Kossenkov AV, et al: Gene expression profiles in peripheral blood mononuclear cells can distinguish patients with non-small cell lung cancer from patients with nonmalignant lung disease. Cancer Res 69: 9202-9210, 2009.
47. McConkey DJ, Lee S, Choi W, Tran M, Majewski T, Lee S, Siefker-Radtke A, Dinney C and Czerniak B: Molecular genetics of bladder cancer: emerging mechanisms of tumor initiation and progression. Urol Oncol 28: 429-440, 2010.
48. Hennig G, Gehrmann M, Stropp U, Brauch H, Fritz P, Eichelbaum M, Schwab M and Schroth W: Automated extraction of DNA and RNA from a single formalin-fixed paraffin-embedded tissue section for analysis of both single-nucleotide polymorphisms and mRNA expression. Clin Chem 56: 1845-1853, 2010.
49. Hoffmann NE, Sheinin Y, Lohse CM, Parker AS, Leibovich BC, Jiang Z and Kwon ED: External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 112: 1471-1479, 2008. (Pubitemid 351441159)
50. Yanagihara N, Caplen N, Bowman E, et al: Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9: 189-198, 2006. (Pubitemid 43357945)
51. Rosenfeld N, Aharonov R, Meiri E, et al: MicroRNAs accurately identify cancer tissue origin. Nat Biotechnol 26: 462-469, 2008. (Pubitemid 351501813)
52. Zhang W, Winder T, Ning Y, et al: A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol 22: 104-109, 2011.
53. Shenouda SK and Alahari SK: MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev 28: 369-378, 2009.
54. Kulpa J, Wojcik E, Radkowski A, Kolodziejski L and Stasik Z: CYFRA 21-1, TPA-M, TPS, SCC-Ag, and CEA in patients with squamous cell lung cancer, and in chemical industry workers as a reference group. Anticancer Res 20: 5035-5040, 2000. (Pubitemid 32319075)
55. Lamy P, Grenier J, Kramar A and Pujol JL: Pro-gastrin-releasing peptide, neuron specific enolase, and chromogranin A as serum markers of small cell lung cancer. Lung Cancer 29: 197-203, 2000.
56. Schneider J, Philipp M, Velcovsky HG, Morr H and Katz N: Pro-gastrin-releasing peptide (ProGRP), neuron specific enolase (NSE), carcinoembryonic antigen (CEA), and cytokeratin 19-fragments (CYFRA 21-1) in patients with lung cancer in comparison to other lung diseases. Anticancer Res 23: 885-893, 2003. (Pubitemid 36750890)
57. Cho WC, Yip TT, Cheng WW and Au JS: Serum amyloid A is elevated in the serum of lung cancer patients with poor prognosis. Br J Cancer 102: 1731-1735, 2010.
58. Cremona M, Calabrò E, Randi G, De Bortoli M, Mondellini P, Verri C, Sozzi G, Pierotti MA, La Vecchia C, Pastorino U and Bongarzone I: Elevated levels of the acute-phase serum amyloid are associated with heightened lung cancer risk. Cancer 116: 1326-1335, 2010.
59. Abdullah M, Marwitz S, Kähler D, Schultz H, Kugler C, Zabel P, Vollmer E and Goldmann T: Pulmonary haptoglobin: a new marker for adenocarcinomas of the lung? Pathology 43: 70-72, 2011.
60. Shah A, Singh H, Sachdev V, Lee J, Yotsukura S, Salgia R and Bharti A: Differential serum level of specific haptoglobin isoforms in small cell lung cancer. Curr Proteomics 7: 49-65, 2010.
61. Coward JI, Nathavitharana R and Popat S: True hypoglycaemia secondary to treatment with granulocyte colony stimulating factor (G-CSF) in a diabetic patient with non-small cell lung cancer. Lung Cancer 75: 133-135, 2012.
62. Song JS, Kim SY, Jo HJ, et al: The role and significance of biomarker for plasma G-CSF in patients with primary lung cancer. Tuber Respir Dis 66: 444-450, 2009.
63. Hanash SM, Pitteri SJ and Faca VM: Mining the plasma proteome for cancer biomarkers. Nature 452: 571-579, 2008. (Pubitemid 351483371)
64. Taguchi A, Politi K, Pitteri SJ, et al: Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20: 289-299, 2011.
65. Jeong HC, Kim GI, Cho SH, Lee KH, Ko JJ, Yang JH and Chung KH: Proteomic analysis of human small cell lung cancer tissues: up-regulation of coactosin-like protein-1. J Proteome Res 10: 269-276, 2011.
66. Du J, Yang S, Lin X, Bu L, Nan Y, Huo S and Shang W: Use of anchorchip-time-of-flight spectrometry technology to screen tumor biomarker proteins in serum for small cell lung cancer. Diagn Pathol 5: 60, 2010.
67. Rahman SM, Gonzalez AL, Li M, et al: Lung cancer diagnosis from proteomic analysis of preinvasive lesions. Cancer Res 71: 3009-3017, 2011.
68. Seydel C: Quantum dots get wet. Science 300: 80-81, 2003.
69. Guha U, Chaerkady R, Marimuthu A, et al: Comparisons of tyrosine phosphorylated proteins in cells expressing lung cancer-specific alleles of EGFR and KRAS. Proc Natl Acad Sci USA 105: 14112-14117, 2008.
70. Haura EB, Müller A, Breitwieser FP, Li J, Grebien F, Colinge J and Bennett KL: Using iTRAQ combined with tandem affinity purification to enhance low-abundance proteins associated with somatically mutated EGFR core complexes in lung cancer. J Proteome Res 10: 182-190, 2011.
71. Zeng X, Hood BL, Sun M, Conrads TP, Day RS, Weissfeld JL, Siegfried JM and Bigbee WL: Lung cancer serum biomarker discovery using glycoprotein capture and liquid chromatography mass spectrometry. J Proteome Res 9: 6440-6449, 2010.
72. Taniguchi K, Uchida J, Nishino K, Kumagai T, Okuyama T, Okami J, Higashiyama M, Kodama K, Imamura F and Kato K: Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res 17: 7808-7815, 2011.
73. Kaiser J: Medicine. Cancer's circulation problem. Science 327: 1072-1074, 2010.
74. Pantel K, Alix-Panabieres C and Riethdorf S: Cancer micrometastases. Nat Rev Clin Oncol 6: 339-351, 2009.